Ovarian cancer remains one of the most lethal gynecologic malignancies, with over 325,000 new cases and 207,000 deaths globally in 2022. In this article, we outline how advances in molecular diagnostics, biomarker-driven stratification, genetic testing (particularly BRCA mutations), and novel therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, checkpoint inhibitors, and CAR-T cell therapies, are expanding treatment options and enabling more personalized approaches. However, ovarian cancer trials present unique operational and scientific challenges, including delayed site activation due to coordination with cooperative groups such as GOG and ENGOT, extremely difficult enrollment in rare subtypes (with rates below 0.1 patients per site per year), and complex regulatory issues involving RECIST criteria interpretation and CA125 response thresholds.
Read our full article to explore the critical challenges and advancements in ovarian cancer clinical trials in-depth.
